JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level

@inproceedings{Lanzillo2014JCVA,
  title={JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level},
  author={Roberta Lanzillo and Raffaele Liuzzi and Luca Vallefuoco and Marcello Moccia and Luca Amato and Giovanni Vacca and Veria Vacchiano and Giuseppe Portella and Vincenzo Brescia Morra},
  booktitle={Therapeutics and clinical risk management},
  year={2014}
}
Natalizumab-treated patients have a higher risk of developing progressive multifocal leukoencephalopathy. Exposure to John Cunningham virus (JCV) is a prerequisite for PML (progressive multifocal leukoencephalopathy). To assess JCV exposure in multiple sclerosis patients, we performed a serological examination, obtained the antibody index, performed real-time polymerase chain reaction (PCR) to detect JCV DNA in plasma and urine, and investigated the role of ultrasensitive C-reactive protein… CONTINUE READING
4 Citations
36 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 36 references

JCV antibodies index on natalizumab treatment: fluctuations and seroconversion

  • R Lanzillo, R Liuzzi, L Amato
  • Multiple Sclerosis Journal
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…